Kantara, C., Moya, S.M., Houchen, C.W., Umar, S., Ullrich, R.L., Singh, P. and Carney, D.H. (2015) Novel regenerative peptide TP508 mitigates radiation-induced gastrointestinal damage by activating stem cells and preserving crypt integrity. Lab Invest. Aug 17.
The TP508 Solution for GI Damage
TP508 Mitigates Radiation Induced GI Damage
About Us
Chrysalis BioTherapeutics, Inc. is committed to helping improve people’s lives through innovation.
Let’s Socialize
Popular Post
Galveston firm to test potential ‘game-changer’ in lung disease treatment
September 29, 2023
Chrysalis Receives FDA Approval to Initiate Clinical Trials with Chrysalin™ (TP508)
GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc. announced today that the US Food and Drug
Galveston firm to test potential ‘game-changer’ in lung disease treatment
GALVESTON An island biopharmaceutical company has received U.S. Food and Drug Administration clearance
Clinical Trials – Tissue Repair
a. Thrombin peptide Chrysalin stimulates healing of diabetic foot ulcers in a placebo-controlled